News
Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Summit Therapeutics Inc. (NASDAQ:SMMT) ranks among the 30 stocks expected to beat the market by 20 percentage points this ...
Zacks Investment Research on MSN3d
Wall Street Analysts Believe Summit Therapeutics (SMMT) Could Rally 63.02%: Here's is How to TradeShares of Summit Therapeutics PLC (SMMT) have gained 2.8% over the past four weeks to close the last trading session at $21.2 ...
Second, SoFi could grow its revenue even without expanding its membership base, by cross-selling additional products to its ...
Alongside her husband, Bob Duggan, Maky Zanganeh has guided cancer drug developer Summit Therapeutics to reach staggering new ...
Revolution Medicines and Summit Therapeutics entered into a clinical collaboration in multiple solid-tumor settings to evaluate their respective treatments in combination with each other. Redwood ...
OpRegen is a suspension of embryonic stem cell-derived RPE cells restoring visual function in degenerative retinal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback